Innovation Serving the Fight Against Cancer
Total Page:16
File Type:pdf, Size:1020Kb
Innovation serving the fight against cancer Under the Aegis of CONTENTS PAGE 4 PAGE 24 GOVERNANCE AND TERRITORY NETWORKING COORDINATION PAGE 28 PAGE 5 ECONOMIC DEVELOPMENT AND KEY FIGURES TRANSFER PAGE 8 PAGE 31 HISTORY PARTNER RELATIONS PAGE 10 PAGE 32 SCIENTIFIC STRENGTHS CLINICAL RESEARCH PAGE 12 PAGE 34 BIBLIOMETRICS SKILLS PAGE 14 PAGE 36 FIELDS OF ACTION INTERNATIONAL PARTNERSHIPS PAGE 16 PAGE 38 EXAMPLES OF NETWORKING FINANCIAL REPORT PAGE 18 PAGE 39 SCIENTIFIC ANIMATION THE NEXT 5 YEARS PAGE 20 EMERGING PROJECTS EDITO CLARA’s 15th anniversary is a great opportunity to look back on the region’s efforts in the fight against cancer since 2003. With unpa- ralleled support from the French State and local authorities, the region’s research teams are remarkable for the significant increase in their scientific output, with nearly 22,000 oncology publica- tions over the past 15 years. Auvergne-Rhône-Alpes now accounts for 22% of France’s cancer publications and the region has shone through its many successes in major national and European inno- vation programs. Stepping up both the quantity and quality of its work, the region’s innovation ecosystem dedicated to the fight against cancer has been successful at creating value. With more than 260 patents filed in 15 years and dozens of start-ups created, Auvergne-Rhône-Alpes has shown its commitment to encouraging science for the benefit of patients and to helping the region grow. 2018 is a year not only to review what CLARA has accomplished, but also to look towards the future thanks to a new 2018-2022 roadmap, drawn up with the INCa and all of the cancer research cluster’s partners. CLARA continues to mobilize, because in order to keep advancing the fight against cancer, we must invest in the long term. The CLARA Team (4) (9) (5) (1) (6) (8) (3) (10) (7) (2) (1) Olivier Exertier, Secretary General (2) Véronique Trillet-Lenoir, Chair Steering Committee (3) Valérie Four, Executive Assistant (4) Arnaud Cutivet, PhD, Project Manager Programming and Scientific Animation (5) Julien Biaudet, Dr in Sociology, Project Officer Social Innovations and Competences Development (6) Ophélie Philipot, PhD, Project Officer Technology Transfer and Economic Development (7) Amandine Scapotta-Garcia, PhD, Project Officer Translational and Clinical Research, Science Popularization (8) Nora Bouhila, Administrative Management (9) Gwenaëlle Paret, Communication Manager (10) Esokia Ridet, Events and Communication Assistant (11) Mylène Honorat, PhD, Project Officer Partnerships and International Relations (absent in the photo) GOVERNANCE AND COORDINATION Members of the Steering Committee Franck Chauvin Charles Jérôme Garin Pierre Hainault Frédérique Alain Puisieux Marina Eduardo Seleiro, Representative Dumontet Representative Representative Penault-Llorca Representative Rousseau- Representative from Jean Representative from CEA from IAB, Representative from CRCL, Tsangaris from IARC, Lyon Monnet from LYric, Lyon Grenoble, Grenoble from IRUCA, Lyon Invited University, Grenoble Clermont- Member, Lyon Saint-Étienne Ferrand MEMBERS OF THE GUIDANCE AND SUPERVISORY BOARD COLLEGE OF PUBLIC AUTHORITIES 16. Saint-Etienne University Hospital, represented by its Managing 1. Prefecture of the Auvergne-Rhône-Alpes region, Director Michaël GALY represented by Prefect Stéphane BOUILLON 17. Clermont-Ferrand University Hospital, represented by its 2. Auvergne-Rhône-Alpes Region, represented by its President Managing Director Didier HOELTGEN Laurent WAUQUIEZ - Represented by Yannick NEUDER, Vice- 18. Lyon CRLCC (Léon Bérard Cancer Center), represented by its President for Higher Education, Research and Innovation / Vice- Managing Director Jean-Yves BLAY President of CLARA’s Guidance and Supervisory Board 19. Clermont-Ferrand CRLCC (Jean Perrin Cancer Center), 3. Lyon Metropole, represented by its President David represented by its Managing Director Frédérique PENAULT- KIMELFELD - Represented by Thierry PHILIP, Vice-President LLORCA for the Environment, Health and Well Being in the City / Vice- President of CLARA’s Steering and Supervisory Board COLLEGE OF COMPANIES ACTIVE IN ONCOLOGY 4. Grenoble Metropole, represented by its President Christophe FERRARI - Represented by Claus HABFAST, Vice-President for 20. Representative of industrial groups, Thierry HULOT, Managing Higher Education, Research, European Relations and Facilities Director, MERCK of Community Interest 21. Representative of SMEs, Emmanuel BLANC Chief Technical 5. Saint-Etienne Metropole, represented by its President Gaël Officer, EDAP TMS PERDRIAU 6. Clermont-Ferrand Metropole, represented by its President COLLEGE OF CHARITY FOUNDATIONS AND ASSOCIATIONS Olivier BIANCHI, represented by Jean-Marc MORVAN, Vice- 22. ARC Foundation for Research on Cancer, represented by its President for Universities, Research, Innovation and Local President Michel PEBEREAU Attractiveness 23. The French League Against Cancer (LNCC), represented by 7. Loire County, represented by its President Georges ZIEGLER its President Jacqueline GODET – Represented by Franck CHAUVIN, Vice-President COLLEGE OF UNIVERSITIES AND SCIENTIFIC ORGANIZATIONS EX-OFFICIO MEMBERS 8. COMUE Lyon Saint-Etienne, represented by its President 24. French National Cancer Institute, represented by its President Khaled BOUABDALLAH Norbert IFRAH 9. Grenoble Alpes University Community, represented by its 25. Léa and Napoléon Bullukian Foundation, represented by Président Lise DUMASY its President Jean-Pierre CLAVERANNE, Vice President of 10. Clermont Auvergne University, represented by its President CLARA’s Guidance and Supervisory Board Mathias BERNARD 11. INSERM Rhône-Alpes Auvergne represented by its Regional PERMANENT GUESTS Representative Dominique PELLA 26. Auvergne-Rhône-Alpes Regional Health Agency (ARS), 12. CEA Tech Grenoble, represented by its Managing Director represented by its Managing Director Jean-Yves GRALL Stéphane SIEBERT 27. LYONBIOPOLE innovation cluster, represented by its 13. International Agency for Research on Cancer, represented by President Christophe CIZERON its Director Christopher WILD 28. MINALOGIC innovation cluster, represented by its President Philippe MAGARSHACK COLLEGE UNIVERSITY HOSPITAL CENTERS 29. Cancéropôle CLARA Chair of the Steering Committee, 14. Lyon Civil Hospitals (HCL), represented by its Managing Véronique TRILLET-LENOIR Director Catherine GEINDRE 30. Cancéropôle CLARA CLARA Secretary General, Olivier 15. Grenoble Alpes University Hospital, represented by its EXERTIER Managing Director Jacqueline HUBERT 4 KEY FIGURES DATA ON INCIDENCE/MORTALITY IN FRANCE Source: Projection of cancer incidence and mortality in metropolitan France in 2017. Technical report. Saint-Maurice: France Public Health. Cepidc, Inserm 400,000 new cases of cancer 150,000 estimated in 2017 in cancer-related metropolitan France deaths in 2017 46% 54% 44% 56% in women in men in women in men (186,000) (214,000) (66,000 deaths) (84,000 deaths) CAUSES OF DEATH OVER THE PERIOD IN AUVERGNE- DUE TO CANCER 2005-2012, RHÔNE-ALPES, (BY ORDER OF FREQUENCY) lthe rate of cancer mortality in France mortality is estimated at over In men: decreased lung, colorectal and prostate 19,000 In women: -2,9% -1,4% people in 2014 breast, lung and colorectal in men in women DATA ON TREATMENT 1,200,000 At the end of 2015, Number of cancer patients hospitalized in France 928 facilities were authorized to treat cancer, including 447,391 Number of hospitalizations for cancer surgery 98 in Auvergne-Rhône-Alpes. Number of chemotherapy 2,659,067 sessions and stays 2,023,591 Number of radiotherapy sessions (not including private sector) 5 15 years of action alongside cancer research stakeholders Initiated and funded by public authorities in sciences and humanities and public health, 2003, the Cancéropôle Lyon-Auvergne-Rhône- placing the patient at the heart of research. Alpes (CLARA) is part of France’s national CLARA is committed to all players in cancer cancer plans. It aims to develop and enhance research with the aim of promoting cross- oncology research in Auvergne-Rhône-Alpes. disciplinary collaboration; since 2005, it has supported projects through funding schemes With 15 years of experience, CLARA brings tailored to their needs. together the region’s academic, clinical and i n d u s t r i a l p l a y e r s i n o r d e r t o b u i l d a r e g i o n a l , A leader in oncology research and transfer in national and international strategy to fight Auvergne-Rhône-Alpes, CLARA is continuing its cancer with a twofold objective: to quickly development in close relation with researchers, transfer research discoveries to patient clinicians and entrepreneurs, and in synergy with care and to create economic value from the ecosystem of value-creation organizations this research. (incubators and innovation clusters), universities, EPSTs and non-profits. In 15 years, CLARA has supported actions to open research to new disciplines, such as the social 13 10 49 scientific business economic forums conventions development projects funded 16 6 50 structuring Franco-Chinese mobility grants projects symposia for young researchers 38 54 4 partner emerging summer sessions companies projects of the Regional funded Oncology School 6 15 years of actions with a productive scientific network Clermont-Ferrand 300 cancer researchers 2 companies developing products for cancer Grenoble Clermont Auvergne 750 cancer researchers University 27 companies developing 1 University Hospital products for cancer Center Grenoble Alpes University 1 Cancer Center 1 University